Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is overvalued on EV/EBITDA, overpriced on P/FC.
Target Price
The average target price of ORX.ST is 38 and suggests 40% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell